Abstract 1235: Impact of anti-CD3 and tumor-target binder affinities on <i>in-vitro</i> potency, <i>in-vivo</i> efficacy, and cytokine release
Omar Abdelmotaleb(Roche (Switzerland)), Christian Klein(Roche (Switzerland)), Thomas Höfer(Heidelberg University), Miro J. Eigenmann(Roche (Switzerland)), Sara Colombetti(Roche (Switzerland)), Alex Odermatt(University of Basel), Anne Freimoser–Grundschober(Roche (Switzerland)), Inja Waldhauer(Roche (Switzerland)), Ali Bransi(Roche (Switzerland)), Peter Brünker(Roche (Switzerland)), Johannes Sam(Roche (Switzerland)), Christian Gassner(Roche (Switzerland)), Anneliese Schneider(Roche (Switzerland)), Martin Lechmann(Roche (Switzerland))
Cited by 1
Related Papers
Charting biologically relevant chemical space: A structural classification of natural products (SCONP)
|Proceedings of the National Academy of Sciences|2005|552
Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation
|The Journal of Cell Biology|2004|468
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis
|Nature Cancer|2022|224
Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection
|Proceedings of the National Academy of Sciences|2003|170